Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
169 participants
INTERVENTIONAL
2019-11-13
2024-02-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Our project is a national translational multicenter genetics study aimed at identifying genes involved in paediatric cancer predisposition by WES in a very select population of children with both developmental delay and cancer. Our project relies on the TED register (Tumeur Et Développement), an initiative by the French organisation SFCE (Société Française de lutte contre les Cancers et les leucémies de l'Enfant et de l'Adolescent) involving 30 child cancer units in France. This database includes the information of more than 500 paediatric cancer patients with congenital abnormalities. The investigators plan to sequence the germline and tumour exome of 100 patients with developmental delay in a trio-design consisting of 300 people and 100 tumours.
The investigators believe that the ExoCaRe project will provide answers to the genetic origins of certain particular childhood cancers. The ExoCaRe project relies on a genetic study to identify genetic risk factors for rare forms of childhood cancer and aims to establish more personalised treatment. It is aimed at improving genetic counselling for families and will be fully integrated in the genetic counselling process. The information provided by our study will be used to improve the management approach to an initial cancer by clarifying the risks of other cancers in related families. The investigators hope to identify new germline genes predisposing to cancer that will be of interest in understanding tumour biology.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors
NCT02756845
Exatecan Mesylate in Treating Patients With Ewing's Sarcoma, Primitive Neuroectodermal Tumor, or Desmoplastic Small Round Cell Tumor
NCT00055952
Exatecan Mesylate in Treating Children With Relapsed or Refractory Rhabdomyosarcoma
NCT00055939
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
NCT05135975
Pharmacogenetically Based Dosing of Thiopurines in Childhood Acute Lymphoblastic Leukemia
NCT01678508
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
-Secondary objectives :
1. Describe inherited predisposition to cancer.
2. Improve genetic counselling processes.
3. Initiate clinical exome sequencing in childhood cancer treatment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
FACTORIAL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cancer patient
* Collection of blood sample or saliva
* Collection of a tumor sample taken before the participation of the patient in study
* Collection of blood sample if tumor sample is not available
Collection of blood sample or saliva
at Inclusion
Collection of a tumor sample taken before the participation of the patient in study
at Inclusion
Collection of blood sample if tumor sample is not available
at Inclusion
Parent of cancer patient
-Collection of blood sample or saliva
Collection of blood sample or saliva
at Inclusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Collection of blood sample or saliva
at Inclusion
Collection of a tumor sample taken before the participation of the patient in study
at Inclusion
Collection of blood sample if tumor sample is not available
at Inclusion
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Child having developed a cancer combined with a delay of development and\\or an intellectual deficiency before the age of 18 years and followed for a cancer of the child in one of hospital center of the Société Française de lutte contre les Cancers et les leucémies de l'Enfant et de l'adolescent (SFCE)
* At least a parent still alive and available to make genetic analyses
* For "Parent of cancer patient" :
* Parent whose child meets the criteria of inclusion of "Cancer patient"
Exclusion Criteria
* Genetic predisposition already identified at the child
* Absence of histological confirmation
* Child died without DNA of the available germinal lineage
* For "Parent of cancer patient" :
* Parent whose child doesn't meets the criteria of inclusion of "Cancer patient"
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Angers
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Isabelle PELLIER, Pr
Role: PRINCIPAL_INVESTIGATOR
UH Angers
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital of Amiens
Amiens, , France
University Hospital of Angers
Angers, , France
Cancer Center Bergonie Institut
Bordeaux, , France
University Hospital of Bordeaux
Bordeaux, , France
University Hospital of Brest
Brest, , France
University Hospital of Clermont Ferrand
Clermont-Ferrand, , France
University Hospital of Dijon
Dijon, , France
University Hospital of Grenoble
Grenoble, , France
University Hospital of Lille
Lille, , France
University Hospital of Limoges
Limoges, , France
Institut of Haematology and Paediatric Oncology of Lyon
Lyon, , France
University Hospital of Marseille
Marseille, , France
University Hospital of Montpellier
Montpellier, , France
University Hospital of Nancy
Nancy, , France
University Hospital of Nantes
Nantes, , France
University Hospital of Nice
Nice, , France
Institut Curie
Paris, , France
University Hospital of Kremlin Bicetre
Paris, , France
University Hospital of Necker
Paris, , France
University Hospital of Trousseau
Paris, , France
University Hospital of Rennes
Rennes, , France
University Hospital of Rouen
Rouen, , France
University Hospital of Saint Etienne
Saint-Etienne, , France
University Hospital of Strasbourg
Strasbourg, , France
University Hospital of Tours
Tours, , France
Institut Gustave Roussy
Villejuif, , France
University Hospital of Saint Denis de La Reunion
Saint-Denis, , Reunion
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017-A01833-50
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.